Selectivity of the P2X3 receptor antagonist Eliapixant, and its potential use in the treatment of endometriosis.

Michelle C Fletcher

Open Access

https://doi.org/10.1007/s11302-021-09831-5

Copy DOI

Journal: Purinergic signalling	Publication Date: Jan 3, 2022
Citations: 3

Abstract

Selectivity of the P2X3 receptor antagonist Eliapixant, and its potential use in the treatment of endometriosis.

Full Text

Published version (

Free)

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Paper Title

Journal

Date

Author